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Abstract Sialic acid storage disease (SASD) is an inborn
error resulting from defects in the lysosomal membrane
protein sialin. The SASD phenotypical spectrum ranges
from a severe presentation, infantile sialic acid storage
disease (ISSD) which may present as hydrops fetalis, to a
relatively mild form, Salla disease. Screening for SASD is
performed by determination of free sialic acid (FSA) in
urine or amniotic fluid supernatant (AFS). Subsequent
diagnosis of SASD is performed by quantification of FSA in
cultured fibroblasts and by mutation analysis of the sialin
gene, SLC17A5. We describe simple quantitative procedures
to determine FSA as well as conjugated sialic acid in
AFS, and FSA in cultured fibroblasts, using isotope
dilution (
13C3-sialic acid) and multiple reaction monitoring
LC-ESI-MS/MS. The whole procedure can be performed in
2–4 h. Reference values in AFS were 0–8.2 μmol/L for
15–25 weeks of gestation and 3.2-12.0 μmol/L for 26–
38 weeks of gestation. In AFS samples from five fetuses
affected with ISSD FSA was 23.9-58.9 μmol/L demon-
strating that this method is able to discriminate ISSD
pregnancies from normal ones. The method was also
validatedfordeterminationofFSAinfibroblasthomogenates.
FSA in SASD fibroblasts (ISSD; 20–154 nmol/mg protein,
intermediate SASD; 12.9-15.1 nmol/mg, Salla disease;
5.9-7.4 nmol/mg) was clearly elevated compared to
normal controls (0.3-2.2 nmol/mg). In conclusion, we
report simple quantitative procedures to determine FSA
in AFS and cultured fibroblasts improving both prenatal
diagnostic efficacy for ISSD as well as confirmatory
testing in cultured fibroblasts following initial screening
in urine or AFS.
Abbreviations
AFS Amniotic fluid supernatant
CSA Conjugated sialic acid
CVS Chorion villus sample
FSA Free sialic acid
IS Internal standard
ISSD Infantile sialic acid storage disease
QC Quality control
SA Sialic acid
SASD sialic acid storage disease
TSA Total sialic acid
Introduction
Sialic acid storage disease (SASD) is an autosomal
recessive disorder resulting from a defect in sialin, a protein
involved in transport of sialic acid (N-acetylneuraminic
acid) across the lysosomal membrane (Suwannarat 2005,
Verheijen et al. 1999). SASD exhibits a broad phenotypical
spectrum (Aula et al. 2000). The main features of a severe
presentation, infantile sialic acid storage disease (ISSD;
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ISSD may present as hydrops fetalis (Froissart et al. 2005,
Lefebvre et al. 1999). A mild presentation, Salla disease
(OMIM 604369), exists mainly in the Finnish population
and is characterised by hypotonia, developmental delay and
ataxia (Varho et al. 2002).
Sialin deficiency results in accumulation of free sialic
acid (FSA) in lysosomes of many cell types. Tissue
accumulation of FSA is reflected by increased excretion
in urine allowing for postnatal screening of SASD by
determination of FSA. Once elevated urinary excretion is
established, confirmation of SASD is possible by quantifica-
tion of FSA in cultured fibroblasts or by mutation analysis of
the sialin gene, SLC17A5 (Verheijen et al. 1999).
Prenatal diagnosis of SASD in families with a known
index case is preferentially performed by mutation analysis
(Aula and Aula 2006). However, to investigate ISSD (along
other possible causes) in prenatal studies of hydrops fetalis,
measurement of FSA in amniotic fluid supernatant (AFS) is
more appropriate as a first screening test.
Traditional methods for determination of sialic acid in
urine and AFS include spectrophotometric or fluorimetric
thiobarbituric acid assays (‘Warren test’), thin-layer chro-
matography (TLC), enzymatic tests and HPLC using UVor
fluorimetric detection (Gopaul and Crook 2006). In the
Warren test interfering substances, such as sugars, may
contribute to absorbance, resulting in false positive meas-
urements, while in TLC a moderate elevation of FSA may
be overlooked. In CVS or cultured fibroblasts/amniocytes
HPLC with pulsed amperometric detection has been used
(Renlund and Aula 1987,R e n l u n de ta l .1986). The
thiobarbituric assay can be used for cell homogenates, but
requires extensive sample clean-up by ion exchange
chromatography (Mancini et al. 1992).
Recently, LC-MS/MS methods have been reported to
quantify FSA in urine (Van der Ham et al. 2007)a n d
cerebrospinal fluid (Van der Ham et al. 2010). In this
report we describe simple quantitative procedures using
LC-MS/MS to assay FSA in AFS as well as in cultured
fibroblasts.
Materials and methods
Reagents
Formic acid (98%), acetonitrile, water (HPLC grade),
ammonium formate (>99% p.a), and sialic acid (N-
acetylneuraminic acid ≥98%) were purchased from Fluka
(St. Louis, MO, USA). Sulfuric acid (95-97%) and
Sialyllactose from human milk (≥ 97%) was obtained
from Sigma-Aldrich (St. Louis, MO). 1,2,3-
13C3-N-
acetylneuraminic acid (internal standard, IS) was obtained
from Omicron Biochemicals (South Bend, IN, USA).
Sample preparation
Amniotic fluid samples (n=151) were obtained from
control pregnancies after routine prenatal testing was
completed in the laboratory of prenatal cytogenetics in our
university hospital. These control pregnancies (not affected
with SASD) were used to determine reference values for
FSA and CSA in the second and third trimester of
pregnancy. Amniotic fluid supernatant (AFS) was pre-
pared by centrifugation for 10 min at 15000 x g.A F S
samples were stored at −80°C for 0–2y e a r s .F i v eA F S
samples from fetuses affected with ISSD were obtained
from the Laboratoire des Maladies Héréditaires du
Métabolisme et Dépistage Néonatal, Centre de Biologie
Est, Hospices Civils de Lyon, France. These samples were
stored at −20°C for 0–7 years prior to FSA determination.
Another 11 AFS samples from control pregnancies (not
affected with SASD), stored at −20°C for 6–8 years, were
used to assess whether storage temperature had an effect
on FSA concentration in AFS. In addition, six AFS
samples from hydrops fetalis pregnancies not caused by
ISSD were analysed.
Fo ran alys isofFSA,25μLofIS(0.85mmol/L)wasadded
to125μLAFS.Foranalysisoftotalsialicacid(TSA)25μlIS
(0.85 mmol/L) was added to 25 μlo fA F S ,f o l l o w e db y
additionof100μLsulphuricacid(63mmol/L)andincubation
for 1 h at 80°C to release all conjugated sialic acid (CSA).
Samples were analysed after cooling down. CSA was
calculated by subtraction of FSA from TSA and expressed
as nmol/mg protein. Protein concentration in AFS was
determined using the Pierce BCA Protein Assay kit (Thermo
Scientific) according to the instructions of the manufacturer.
Skin fibroblast cultures of 10 patients carrying a deficiency
of sialin (six affected with ISSD, two with intermediate form
of SASD and two with Salla disease) as well as cultures from
24 controls (not affected with SASD) were provided by the
EuropeanCellBank,Rotterdam,TheNetherlands.Fibroblasts
were cultured under standard conditions in Ham’s F10
medium supplemented with 10% fetal calf serum, harvested
by trypsinisation and stored as cell pellets at −80°C. A cell
pellet was prepared from one 75 cm
2 flask. Homogenates
were prepared by resuspending one cell pellet in 200 μLo f
IS (85 μmol/L) followed by sonication for 10 sec at 130 W.
Ten μL of homogenate was taken out to determine protein as
described above. For analysis of FSA, 300 μLo fa c e t o n i t r i l
was added to the remaining cell homogenate. Following
mixing the solution was centrifuged (10 min at 15000 × g)
and the supernatant was transferred to a glass vial and dried
under a flow of nitrogen. The residue was dissolved in
200 μL HPLC water and analysed.
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An eight-point calibration curve with concentrations of 0, 5,
10, 50, 100, 200, 425 and 850 μmol/L SA in HPLC water
was prepared. To 125 μL of each of the standards 25 μLo f
IS (0.85 mmol/L) was added.
LC-MS/MS
The LC-MS/MS system consisted of a TSQ Quantum triple
quadrupole mass spectrometer, interfaced with an electron
spray ionisation source (Thermo Scientific, USA)
connected to a Surveyor autosampler and Surveyor MS
Pump Plus (Thermo Sientific). Using the autosampler 10 uL
aliquots of samples or standards were injected onto a
Waters dC18 guard column (3.5 μm, 2.1 × 20 mm)
connected to a Waters Atlantis dC18 analytical column
(3.5 μm, 2.1 × 100 mm) (Waters, Massachusetts, USA).
The analytical column temperature was kept at 35°C and
flow rate was 0.3 mL/min. The following elution profile
was used: 0–4 min, linear gradient from 100% solvent A
(0.05 M ammoniumformate, pH 3.0) to 100% solvent B
(100% acetonitrile); 4–6 min 100% solvent B; 6–12 min
100% solvent A. Between 0–2.5 min and 6.13-12 min
the solvent was sent to waste using a divert valve to
avoid unnecessary introduction of solvents in the source.
The retention time of SA and IS was 5 min.
The MS/MS was operated in the negative mode with a
capillary voltage of 5.0 kV. The tube lens settings for SA
and IS were 88 and 93 V respectively. As a drying gas
nitrogen (sheath gas and auxiliary) was used at a flow rate
of 50 and 30 L/min respectively, with a source temperature
of 325°C. The collision cell was operated at 28 eV at a gas
pressure of 1.4 mTorr Argon. Mass resolution of Q1 and Q3
quadrupoles was 0.7 Da. Detection was performed by
selecting negatively single charged SA ions m/z 308.0>86.9
and IS m/z 311.0>89.9. Xcalibur software (Version 1.4,
SP3, Thermo Finnigan, USA) was used for instrument
control, data acquisition and data processing.
Method validation
Linearity was determined with nine different concentrations
of FSA up to 1700 μmol/L and eight different concen-
trations of sialyllactose up to 1000 μmol/L. Hydrolysis of
sialyllactose was performed as described for CSA in AFS
(see above). Limit of detection (LOD, signal-to-noise ratio
3:1) and limit of quantitation (LOQ, signal-to-noise ratio
10:1) were determined using a 5 μmol/L SA standard, four
AFS samples containing 1.2-12 μmol/L FSA and four
fibroblast homogenates containing 0.7-4.9 μmol/L FSA.
Recovery was evaluated by addition of 49 or 106 nmol FSA
and57nmolsialyllactoseto500μLAFSand1.5nmolFSAto
300 μL fibroblast homogenate. Precision (intra-assay and
inter-assayvariation)was assessedwithtwoQCAFSsamples
containing 4.3 (normal) and 38.1 (high) μmol/L FSA and
194 and 274 μmol/L CSA respectively.
Results
Amniotic fluid supernatant
Calibration curves were linear (R
2 0.999) up to at least
1700 μmol/L for FSA and 1000 μmol/L for TSA
(sialyllactose). Limit of detection (LOD) was 0.13 μmol/L
for FSA and 0.6 μmol/L for TSA. Limit of quantitation
(LOQ) was 0.36 μmol/L for FSA and 1.9 μmol/L for TSA.
Intra-assay variation coefficients in AFS were 8.5% for
FSA and 8.9% for CSA. Inter-assay variation of FSA in
two QC samples was 19.4% (FSA 4.3 μmol/L) and 12.4%
(FSA 38.1 μmol/L). For CSA, inter-assay variation in these
two QC samples was 14.2% (CSA 194 μmol/L) and 14.4%
(CSA 274 μmol/L). Recovery was 85-94% for FSA and
82–86% for CSA (sialyllactose).
Reference values for FSA in AFS were 2.8±1.8 μmol/L
(average±SD; range 0–8.2, n=108) for gestational age
15–25 weeks and 6.8±2.3 μmol/L (range 3.2-12.0, n=43)
for gestational age 26–38 weeks. While the AFS samples
used to determine reference values were stored at −80°C,
we tested whether storage at −20°C resulted in different
FSA concentration, e.g. higher values due to release of
C S A .F S Av a l u e si n1 1A F Ss a m p l e ss t o r e df o r6t o
8 years at −20°C were all within the reference range
determined with samples stored at −80°C. FSA concen-
tration in AFS from five fetuses affected with ISSD
ranged from 23.9 to 58.9 μmol/L and was clearly
different from control values (Fig. 1). In six AFS samples
from hydrops fetalis pregnancies with other cause, FSA
values were within reference range (2.4-4.9 μmol/L, n=4,
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Fig. 1 Free sialic acid in amniotic fluid supernatant samples as a
function of gestational age. Legend: + control samples (n=151), ● ISSD
samples
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gestational age 30 and 33 weeks).
CSA was expressed as nmol/mg protein, since a positive
correlation existed between the concentrations of protein
and CSA. Reference values for CSA were 41±16 nmol/mg
protein (average±SD; range 7–89, n=103) for gestational
age 15–25 weeks and 60±20 nmol/mg protein (average±SD;
range 26–102, n=24) for gestational age 26–38 weeks.
Fibroblasts
The limit of quantitation determined for FSA in fibro-
blast homogenates was 0.18 μmol/L. Recovery of FSA
was 104%. Reference values for FSA in fibroblast
homogenates were 1.0±0.7 nmol/mg protein (average±
SD; range 0.3-2.2, n=24). FSA measured in six fibro-
blast homogenates of patients known to be affected with
ISSD was 20–154 nmol/mg protein with a median value
of 31 nmol/mg protein. In two samples of patients with
an intermediate form of SASD FSA was 12.9 and
15.1 nmol/mg protein, while in two samples of patients
with Salla disease FSA was 5.9 and 7.4 nmol/mg protein.
Discussion
Sialic acid storage disease (SASD) may present with
variable clinical severity. The most severe phenotype is
hydrops fetalis (Froissart et al. 2005; Lefebvre et al. 1999).
A number of other lysosomal storage disorders may also
present as hydrops fetalis (Stone and Sidransky 1999) and
diagnostic tests to investigate the cause of hydrops fetalis
should include assays for these lysosomal disorders (Piraud
et al. 1996; Kooper et al. 2006). To date HPLC has been the
preferred method to measure FSA in AFS (Aula and Aula
2006). Other existing methods for determination of FSA in
AFS such as the colorimetric Warren test or TLC have
limited specificity or sensitivity or consist of elaborate
procedures. The method described here combines high
specificity and sensitivity with very simple sample
preparation. FSA determination merely requires mixing
of an AFS sample with a sialic acid stable isotope
solution, immediately followed by LC-MS/MS. The
whole procedure including sample preparation, analysis
and calculation of results can be performed in 2–4h .T h e
reference values described here (0–6.3 μmol/L; 95 %
confidence interval for gestational age 15–25 weeks)
appear to be similar to previously published values deter-
mined by the thiobarbiturate assay (1.7-5.3 μmol/L; Aula and
Aula 2006). FSA concentrations in AFS samples from
five fetuses affected with ISSD (23.9 to 58.9 μmol/L)
were 2- to 9-fold the upper limit of the corresponding
reference values and demonstrate that this method is able
to distinguish ISSD pregnancies from normal controls.
Interestingly, our results suggest that FSA is stable for at
least 8 years of storage at −20°C enabling retrospective
diagnosis of ISSD. Our method may also be useful for
prenatal diagnosis of ISSD in families with an ISSD index
case with no additional molecular workup. Cases of Salla
disease may only have mildly elevated FSA concentra-
tions in AFS and in these instances the preferred method
of prenatal diagnosis is mutation testing in a chorionic
villus biopsy (Aula and Aula 2006).
In addition to measurement of FSA, we have performed
analytical validation of CSA determination in AFS. Increased
CSA in AFS has been reported in cases of sialidosis and
galactosialidosis (Piraud et al. 1996; Kooper et al. 2006).
Since sialidosis or galactosialidosis AFS samples were not
available to us, we have not been able to establish the efficacy
of our method in prenatal screening of these diseases.
Following demonstration of an elevated concentration of
FSA in urine or AFS, confirmation of SASD is possible
by quantification of FSA in cultured fibroblasts or
amniocytes (Seppala et al. 1991; Renlund and Aula
1987). We show that our LC-MS/MS method is able to
establish diagnosis of SASD in cultured fibroblasts.
Reference values determined by LC-MS/MS (1.0±
0.7 nmol/mg protein) are fully compatible with previously
reported values determined by the thiobarbiturate assay
(1.0±0.6 nmol/mg protein; Seppala et al. 1991)a n d
f i b r o b l a s t so fI S S Dp a t i e n t sa sw e l la sS a l l ad i s e a s ea n d
SASD of intermediate severity contain elevated FSA
levels compared to control fibroblasts. Moreover, the level
of FSA correlated with the severity of disease. Sample
preparation is simple and can be completed within an hour,
which is much faster than HLPC or, in particular, the
thiobarbituric assay which requires extensive sample
clean-up by ion exchange chromatography. Our method
m a ya l s ob eu s e f u lt os c r e e nf o rI S S Di nC V So r
amniocytes, but this needs to be validated.
In conclusion, this report describes simple quantitative
procedures using LC-MS/MS to assay free and conjugated
sialic acid in amniotic fluid supernatant as well as free sialic
acid in cultured fibroblasts.
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